Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-04-11
2006-04-11
Gambel, Phillip (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387100, C530S387300, C530S388100, C530S388250, C424S130100, C424S141100, C424S001210, C424S158100
Reexamination Certificate
active
07026456
ABSTRACT:
The present invention relates to novel p75 heterodimer specific anti-human IL-12 antibodies that are characterized by a higher potency and greater efficacy in neutralizing human IL-12 bioactivity than known heterodimer specific IL-12 monoclonal antibodies. The heterodimer specific antibodies recognize one or more epitopes of the human IL-12 p75 heterodimer, but do not bind to the p40 subunit alone. The heterodimer specific IL-12 antibodies neutralize rhesus monkey IL-12 bioactivity with a potency similar to their potency for neutralizing human IL-12 bioactivity making them useful IL-12 antagonists for in vivo studies in the rhesus monkey.
REFERENCES:
patent: 4473555 (1984-09-01), Nestor, Jr. et al.
patent: 4569794 (1986-02-01), Smith et al.
patent: 5457038 (1995-10-01), Trinchieri et al.
patent: 5569454 (1996-10-01), Trinchieri et al.
patent: 5648072 (1997-07-01), Trinchieri et al.
patent: 5648467 (1997-07-01), Trinchieri et al.
patent: 5650492 (1997-07-01), Gately et al.
patent: 5780597 (1998-07-01), Gately et al.
patent: 5811523 (1998-09-01), Trinchieri et al.
patent: 5853697 (1998-12-01), Strober et al.
patent: 5853721 (1998-12-01), Gately et al.
patent: 6225117 (2001-05-01), Gately et al.
patent: 0 357 067 (1990-03-01), None
patent: 0 433 827 (1991-06-01), None
patent: 0677533 (1995-10-01), None
patent: WO 90/05147 (1990-05-01), None
patent: WO 92/05256 (1992-04-01), None
patent: WO 95/24918 (1995-09-01), None
patent: WO 98/34635 (1998-08-01), None
Bendig, M.M. Methods: A Companion to Methods in Enzymology. vol. 8: 83-93, 1995.
Cytokine Bulletin. Genzyme, pp. 1-13, Spring 1996.
Colman (Res Immunol. Jan. 1994;145(1):33-6).
Gubler, et al., Coexpression Of Two Distinct Genes Is Required To Generate Secreted Bioactive Cytotoxic Lymphocyte Maturation Factor, Proc. Natl. Acad. Sci., vol. 88, pp. 4143-4147 (1991).
Wolf, et al., Cloning Of cDNA For Natural Killer Cell Stimulatory Factor, A Heterodimeric Cytokine With Multiple Biologic Effects On T And Natural Killer Cells, The Journal of Immunology, vol. 146, pp. 3074-3081 (1991).
Podlaski, et al., Molecular Characterization Of Interleukin 12, Archives Of Biochemistry And Biophysics, vol. 294, No. 1, pp. 230-237 (1992).
D-Andrea, et al., Production Of Natural Killer Cell Stimulatory Factor (Interleukin 12) By Peripheral Blood Mononuclear Cells, J. Exp. Med, vol. 176, pp. 1387-1398 (1992).
Ling, et al., Human IL-12 p40 Homodimer Binds To The IL-12 Receptor But Does Not Mediate Biologic Activity, The Journal of Immunology , vol. 154, pp. 116-127 (1995).
Gillessen, et al., Mouse Interleukin-12 (IL-12) p40 Homodimer: A Potent IL-12 Antagonist, Eur. J. Immunol., vol. 25, pp. 200-206 (1995).
Chizzonite, et al., High and Low Affinity Receptors For Interleukin-12 (IL-12) On Human T-cells: Evidence For A Two Subunit Receptor By IL-12 And Anti-Receptor Antibody Binding, 2ndInternational Cytokine Conference, Banff, Alberta, Oct. 1-5, 1994, vol. 6:A82a (Abstract) ( 1994).
Gately, et al., Measurement Of Human And Mouse Interleukin 12, Current Protocols In Immunology, vol. 1, J.E. Coligan, et al. eds., John Wiley & Sons, pp. 6.16.1-6.16.8 (1995).
Mattner, et al., Genetically Resistant Mice Lacking Interleukin-12 Are Susceptible To Infection With Leishmania Major And Mount A Polarized Th2 Cell Response, Eur. J. Immunol, vol. 26, pp. 1553-1559 (1996).
Magram, et al, IL-12-Deficient Mice are Defective in IFNγ Production and Type 1 Cytokine Responses, Immunity, vol. 4, pp. 471-481 (1996).
Chizzonite, et al., IL-12: Monoclonal Antibodies Specific For The 40-kDa Subunit Block Receptor Binding And Biologic Activity On Activated Human Lymphoblasts, The Journal Of Immunology, vol. 147, No. 5, pp. 1548-1556 (1991).
Stern, et al., Increasing The Antigen Binding Capacity Of Immobolized Antibodies, Technigues In Protein Chemistry IV, pp. 353-360 (1993).
Zhang, et al., Interleukin 12 At The Site Of Disease In Tuberculosis, J. Clin. Invest., vol. 93, pp. 1733-1739 (1994).
Sieling, et al., IL-12 Regulates T. Helper Type 1 Cytokine Responses In Human Infectious Diseases, The Journal of Immunology , vol. 153, pp. 3639-3647 (1994).
Presky, et al., Evidence for Mutiple Sites of Interaction between IL-12 and Its Receptor, Annals of the New York Academy of Science, vol. 795, pp. 390-393 (1996).
Carter, et al., Production and Characterization of Monoclonal Antibodies to Human Interleukin-12, Hybridoma, vol. 16, No. 4 (1997).
Zou, et al., Structure-Function Analysis of the p35 Subunit of Mouse Interleukin 12, Journal of Biology Chemistry, vol. 270, No. 11, pp. 5864-5871 (1995).
Aggarwal, 1987, in:Protein Purification: Micro to Macro, Richard Burgess, ed., Alan R. Liss, Inc., p. 22.
Bowie et al., 1990, “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions”, Science 247:1306-1310.
Casagli et al., 1987, “Purification of Recombinant Human Interleukin 1β Produced from Yeast”, in:Protein Purification: Micro to Macro, Richard Burgess, ed., Alan R. Liss, Inc., pp. 421-427.
Chan et al., 1992, “Mechanisms of IFN-γ Induction by Natural Killer Cell Stimulatory Factor (NKSF/IL-12). Role of Transcription and mRNA Stability in the Synergistic Interaction between NKSF and IL-2”, J. Immunol. 148:92-98.
Chan et al., 1991, “Induction of Interferon-γ Production by Natural Killer Cell Simulatory Factor: Characterization of the Responder Cells and Synergy with Other Inducers”, J. Exp. Med. 173:869-879.
Chehimi et al., 1992, “Natural Killer (NK) Cell Stimulatory Factor Increases the Cytotoxic Activity of NK Cells from both Healthy Donors and Human Immunodeficiency Virus-Infected Patients”, J. Exp. Med. 175:789-796.
Chizzonite et al., 1991, “Cytotoxic Lymphocyte Maturation Factor (CLMF): Receptor on PHA-Activated Peripheral Blood Lymphoblasts (PHA-PBL) Mediated Binding and Biological Activity”, FASEB J. 5:5568.
Cohen, 1995, “IL-12 Deaths: Explanation and a Puzzle”, Science 270:908.
Desai et al., 1991, “Regulation of Human Lymphocyte Proliferation by Cytotoxic Lymphocyte Maturation Factor (CLMF)”, FASEB J. 5:2069.
Devos et al., 1983, “Molecular Cloning of Human Interleukin 2 cDNA and Its Expression inE. coli”, Nucl. Acids Res. 11:4307-4323.
Gately et al., 1991, “Regulation of Human Lymphocyte Proliferation by a Heterodimeric Cytokine, IL-12 (Cytotoxic Lymphocyte Maturation Factor)”, J. Immunol. 147:874-882.
Gately et al., 1990, “Isolation and Characterization of a Novel Lymphokine which Synergizes with IL-2 in the Generation of Activated NK/LAK Cells”, Lymphokine Res. 9:566.
Gately et al., 1986, “Synergy between Recombinant Interleukin 2 (rIL 2) and IL 2-Depleted Lymphokine-Containing Supernatants in Facilitating Allogeneic Human Cytolytic T Lymphocyte Responses in vitro”, J. Immunol. 136:1274-1282.
Gately et al., 1985, “Synergy between Recombinant Interleukin 2 (rIL 2) and IL 2-Depleted Lymphokine-Containing Supernatans in Facilitating Human Cytoytic T Lymphocyte Responses in vitro”, Fed. Proc. 44:947.
Gately et al., 1982, “In vitro Studies on the Cell-Mediated Immune Response to Human Brain Tumors. I. Requirement for Thrid-Party Stimulator Lymphocytes in the Induction of Cell-Mediated Cytotoxic Responses to Allogeneic Cultured Gliomas”, J. Natl. Cancer Inst. 69:1245-1254.
Gately et al., 1991, “Interleukin 12: A Novel Heterodimeric Cytokine with Potential Antitumor Applications”, Neuroimmunol. Res. 4:20-32.
Gearing and Cosman, 1991, “Homology of the p40 Subunit of Natural Killer Cell Stimulatory Factor (NKSF) with the Extracellular Domain of the Interleukin-6 Receptor”, Cell 66:9-10.
Gubler et al., 1991, “Cloning and Expression of Cytotoxic Lymphocyte Maturation Factor (CLMF), a Heterodimeric Lymphokine that Potentiates NK, LAK and T-Cell Responses”, Abs. J. Cellular Biochem. Suppl. 15F:70.
Herberman and Ortaldo, 1981, “Natural Killer Cells: Their Roles in Defenses against Disease”, S
Gately Maurice Kent
Presky David Howard
Gambel Phillip
Hoffman-La Roche Inc.
Jones Day
Ouspenski Ilia
LandOfFree
Antibodies against human IL-12 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies against human IL-12, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies against human IL-12 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3561911